For the treatment of myasthenia gravis.
Pyridostigmine inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine.
Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.
3 hours following oral administration.